NCT06429397 - Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

May 1, 2027

Study Completion Date

May 28, 2027

Conditions

Pheochromocytoma

Interventions

DRUG

Anlotinib and Benmelstobart

Enrolled patients received a treatment cycle every 21 days: 200mg of piamprizumab was given intravenously on the first day of treatment, and 12mg of anrotinib hydrochloride capsule was given continuously for 14 days and suspended for 7 days.

Trial Locations (1)

510060

Cancer Center, Sun Yat-sen University, Guangzhou